- Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the long-lasting pandemic coronavirus disease 2019 (COVID-19), with dramatic clinical, social, and economic implications. Importantly, evolving experience consistently shows that, in addition to issues related to the acute phase, patients who recover from COVID-19 may present a wide variety of bothersome symptoms, which may be debilitating and significantly impair their quality of life. This condition, when it persists beyond 12 weeks after recovery, is defined as “post–COVID-19” or “long COVID-19” syndrome.
- The coronavirus disease 2019 (COVID-19) pandemic has presented a once in a generation challenge to our health care systems worldwide. In its early phases, confusion existed about modes of transmission, levels of infection control, and risk to health care personnel. This combined with lack of resources for adequate personal protective equipment (PPE) generated high levels of anxiety for medical teams and rationing of PPE in the early phase. Advise and local guidelines were changing on an almost daily basis, with major challenges in procedural risk assessment in the absence of immediate polymerase chain reaction testing: COVID-19 positivity was assumed until proven otherwise.
- With 10 vaccines currently approved and another 81 potentially to be approved in the coming months, the focus on the coronavirus disease 2019 (COVID-19) pandemic has changed from confinement to elimination. However, it is a known viral law that when the going gets tough, the tough get going, with natural selection bringing forth the most favorable mutations. Among these, the most worrying were found in South Africa, Brazil, and the United Kingdom, of which the latter initially has been designated as a “variant of concern.” Early research shows that mutations in these variants might (partly) escape the immune response.
- Since its emergence from Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), has claimed the lives of >1.7 million individuals worldwide and >317,000 individuals in the United States alone (as of December 21, 2020, 1 PM CST).1,2 Although the acute respiratory and thrombotic complications of COVID-19 seem to explain much of the observed morbidity and mortality, cardiac involvement, including myocardial infarction, myocarditis, and life-threatening ventricular arrhythmias,3–5 seems to be relatively common.
- In a crisis, be aware of the danger—but recognize the opportunity.John Fitzgerald Kennedy
- In December 2019, the Chinese public health authorities reported several cases of acute respiratory syndrome in the city of Wuhan caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2 In our hyperconnected world, the initial outbreak underwent unprecedented dissemination and has now become this century’s worst pandemic, with more than 8 million people infected and almost 450,000 deaths to date.3
- During the COVID-19 pandemic and with worldwide medical colleagues, the electrophysiology (EP) community has encountered challenges that are unique in our collective consciousness. Just a few short weeks ago, we focused on accessory pathway potentials, or local abnormal ventricular activation, or pulmonary vein potentials, and/or those from the His bundle. Now, our expanded focus on “potentials” includes arenas outside the EP laboratory as we expand our partnership with procedure centers, hospitals, regions, nations, and the world.